SEC Form 4 · accession 0001387131-17-002047
Ohr Pharmaceutical Inc · OHRP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Orin Hirschman
Director
Period of report
Apr 10, 2017
Accepted (ET)
Apr 13, 2017 · 11:11 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001173281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF1 | Apr 10, 2017 | P | 142,858 | $0.70 | A | 1,649,605 | I | By AIGH Investment Partners, LLC |
| Common Stock, par value $0.0001 per share | holding | — | — | — | 138,200 | I | By self as custodian of accounts for the benefit of minor children. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants (right to buy) | $1.00 | Apr 10, 2017 | P | 100,001 | A | Apr 10, 2017 | Apr 10, 2022 | Common Stock | 100,001 | 100,001 | D |
Explanation of responses
- F1On April 5, 2017, Ohr Pharmaceutical, Inc. (the "Issuer") entered into a securities purchase agreement (the "Securities Purchase Agreement") with various purchasers set forth on the signatures pages thereto, including the Reporting Person. Pursuant to the Securities Purchase Agreement, the Reporting Person purchased shares of the Issuer's common stock (the "Common Stock") and warrants to purchase shares of Common Stock in a registered offering (the "Offering") for an aggregate purchase price of $100,000.06. The closing of the Offering occurred on April 10, 2017.